Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome

Annals of Neurology

Volumn 51, Issue 6, 2002, Pages 673-680

  Buchwald, Brigitte ^a   Ahangari, Raheleh ^a   Weishaupt, Andreas ^a   Toyka, Klaus V ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; FEMALE; GUILLAIN BARRE SYNDROME; HEMIDIAPHRAGM; HUMAN; IMMUNOTHERAPY; MALE; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTIBODIES, BLOCKING; CHILD; GANGLIOSIDES; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MICE; MICE, INBRED BALB C; PATCH-CLAMP TECHNIQUES; SYNAPTIC TRANSMISSION;

EID: 0036264525     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10205     Document Type: Article

References (38)

1. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part I
2. Pathogenesis of Guillain-Barré syndrome
3. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes
4. Human autoimmune neuropathies
5. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: A macro-patch-clamp study
6. Prognostic value of electrodiagnosis in Guillain-Barré syndrome
7. Single fiber electromyography in early Guillain-Barré syndrome: Discrepancy between jitter and blocking
8. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
9. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatment in Guillain-Barré syndrome
10. Intravenous immune globulin is also an efficient therapy of acute Guillain-Barré syndrome in affected children
11. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
12. Assessment of current diagnostic criteria for Guillain-Barré syndrome
13. The Guillain-Barré syndrome
14. Electro-physiological classification of Guillain-Barré syndrome: Clinical associations and outcome
15. Immunoglobulin G from patients with Millet-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice
16. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals
17. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders
18. Calcium dependence of quantal release triggered by graded depolarisation pulses to nerve terminals on crayfish and frog muscle
19. IgM anti-GM1 antibodies in the Guillain-Barré syndrome: A serological predictor of the clinical course
20. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases
21. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg
22. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin
23. Spontaneous recovery from the Guillain-Barré syndrome is associated with antiidiotypic antibodies recognizing a cross-reactive idio-type on anti-neuroblastoma cell line antibodies
24. Anti-idiotypes against autoantibodies in normal immunoglobulins: Evidence for network regulation of human autoimmune responses
25. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes
26. Intravenous immune globulin affects cytokine production in T lymphocytes and monocyres/macrophages
27. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome
28. An endogenous penapepride acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system
29. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies
30. Intravenous γ-globulin inhibits binding of anti-GM1 to its target antigen
31. Normal human plasma contains antibodies that specifically block neuropathy-associated human anti-GM1 IgG-antibodies
32. Prevention of passively transferred experimental autoimmune myashenia gravis by Fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor
33. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: Inhibition in vitro and in vivo by IV immunoglobulin
34. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy
35. Detection of antibodies to gangliosides and glycolipids in various intravenous immunoglobulin (IVIg) preparations
36. Intravenous immunoglobulin treatment of neurological autoimmune diseases
37. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates